Leah SibenerHead of Therapeutic Discovery, Co-Founder at 3T Biosciences, USA
Leah is a co-founder and VP and Head of Therapeutic Discovery at 3T Biosciences. At 3T she leads the R&D operations and strategy focusing on identifying new immunotherapy targets, and engineering T cell receptor based therapeutics. Leah has co-authored work in high-impact journals such as Cell, Science, Nature Immunology, Immunity, Elife, Nature Genetics, and PNAS. She holds a Bachelor’s degree in Biophysics from Johns Hopkins University, and a PhD in Immunology from Stanford University where she developed 3T’s target discovery platform in Chris Garcia’s research group. She was named one of Forbes’ 2018 30-under-30 in Healthcare. Prior to Stanford and 3T, Leah was a part of research teams at the Johns Hopkins Institute for Cellular Engineering in Jonathan Schneck’s Lab, as well as at Genentech in Early Discovery Immunology.